Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rdGCM-1013
- Development stage
- Preclinical
- Lead developer
- Gencellmed
- Modality
- Gene Therapies
- Administration
- Intratumoral, Intravenous, Intraperitoneal
01
Overview
rdGCM-1013 is a preclinical gene therapy candidate developed by Gencellmed for aesthetic applications, specifically targeting wrinkle care. The therapy utilizes a replication-defective Herpes Simplex Virus type 1 (HSV-1) viral vector to deliver therapeutic genetic material to the skin. By leveraging the large cargo capacity and natural skin-cell infectivity of HSV-1, while ensuring safety through the removal of replication-essential genes, rdGCM-1013 is designed to provide localized treatment for skin rejuvenation. The specific therapeutic gene and molecular target have not been publicly disclosed by the developer.
Beyond the preview
Go deeper on rdGCM-1013.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rdGCM-1013.